Skanska to be construction partner for R&D center and corp HQ for AstraZeneca, UK, for around GBP 300 M, about SEK 3.7 billion
Skanska has won a contract for the construction management of a research and development center and corporate headquarters for AstraZeneca in the UK. The contract is worth around GBP 300 M, about SEK 3.7 billion, which will be included the order in the order bookings for Skanska UK in the first quarter of 2015.
Work has started and is expected to be completed in 2017. The client will begin occupying the site at the end of 2016.
Skanska UK reported revenues of about SEK 15 billion in 2014. It has around 5,000 employees. The company is active in building and civil construction, utilities and building services, as well as facilities management and commercial development. In the UK, Skanska is a leader in public private partnerships, PPPs, also known as Privately Financed Initiatives, PFIs.